CoChat

Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway

Open access
Mo, Dongliang, Fang, Hongbo, Niu, Kaifeng, Liu, Jing, Wu, Meng, Li, Shiyou, Zhu, Tienian, Aleskandarany, Mohammed A., Arora, Arvind, Lobo, Dileep N., Madhusudan, Srinivasan, Balajee, Adayabalam S., Chi, Zhenfen, Zhao, Yongliang · 2016 · Cancer Research
Cited by 101

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Elevation of the DNA-unwinding helicase RECQL4, which participates in various DNA repair pathways, has been suggested to contribute to the pathogenicity of various human cancers, including gastric cancer. In this study, we addressed the prognostic and chemotherapeutic significance of RECQL4 in human gastric cancer, which has yet to be determined. We observed significant increases in RECQL4 mRNA or protein in >70% of three independent sets of human gastric cancer specimens examined, relative to normal gastric tissues. Strikingly, high RECQL4 expression in primary tumors correlated well with poor survival and gastric cancer lines with high RECQL4 expression displayed increased resistance to cisplatin treatment. Mechanistic investigations revealed a novel role for RECQL4 in transcriptional regulation of the multidrug resistance gene MDR1, through a physical interaction with the transcription factor YB1. Notably, ectopic expression of RECQL4 in cisplatin-sensitive gastric cancer cells with low endogenous RECQL4 was sufficient to render them resistant to cisplatin, in a manner associated with YB1 elevation and MDR1 activation. Conversely, RECQL4 silencing in cisplatin-resistant gastric cancer cells with high endogenous RECQL4 suppressed YB1 phosphorylation, reduced MDR1 expression, and resensitized cells to cisplatin. In establishing RECQL4 as a critical mediator of cisplatin resistance in gastric cancer cells, our findings provide a therapeutic rationale to target RECQL4 or the downstream AKT–YB1–MDR1 axis to improve gastric cancer treatment. Cancer Res; 76(10); 3057–66. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2361

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 101

Metadata

Authors
Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., Madhusudan, S., Balajee, A. S., Chi, Z., & Zhao, Y.
Venue
Cancer Research
Published
2016-05-12
Volume
76
Issue
10
Pages
3057-3066
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2308504656
Cited by
101
References
5
FWCI
3.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2361
The paper
Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., Madhusudan, S., Balajee, A. S., Chi, Z., & Zhao, Y. (2016). Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.